CytomX Therapeutics, Inc. (CTMX) Downgraded by ValuEngine to Sell
ValuEngine cut shares of CytomX Therapeutics, Inc. (NASDAQ:CTMX) from a hold rating to a sell rating in a research note issued to investors on Friday.
A number of other analysts have also recently weighed in on CTMX. Zacks Investment Research cut shares of CytomX Therapeutics from a buy rating to a hold rating in a research note on Monday, May 29th. Jefferies Group LLC reissued a buy rating and issued a $25.00 target price on shares of CytomX Therapeutics in a research note on Tuesday, June 6th. Cowen and Company reissued a buy rating on shares of CytomX Therapeutics in a research note on Wednesday, June 28th. BidaskClub raised shares of CytomX Therapeutics from a sell rating to a hold rating in a research note on Saturday, July 8th. Finally, Cann reissued a hold rating on shares of CytomX Therapeutics in a research note on Tuesday, August 8th. Two equities research analysts have rated the stock with a sell rating, four have issued a hold rating and six have given a buy rating to the stock. CytomX Therapeutics currently has a consensus rating of Hold and a consensus target price of $25.67.
Shares of CytomX Therapeutics (NASDAQ:CTMX) traded up 4.28% during trading on Friday, reaching $17.31. The company’s stock had a trading volume of 1,152,874 shares. The stock’s market capitalization is $638.17 million. CytomX Therapeutics has a 1-year low of $9.85 and a 1-year high of $20.02. The company’s 50-day moving average price is $15.25 and its 200 day moving average price is $15.24.
CytomX Therapeutics (NASDAQ:CTMX) last posted its earnings results on Monday, August 7th. The biotechnology company reported ($0.69) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.39) by ($0.30). The business had revenue of $8.75 million during the quarter, compared to the consensus estimate of $4.95 million. CytomX Therapeutics had a negative net margin of 206.33% and a negative return on equity of 84.61%. Analysts anticipate that CytomX Therapeutics will post ($1.49) EPS for the current year.
TRADEMARK VIOLATION WARNING: This report was posted by Daily Political and is the property of of Daily Political. If you are reading this report on another site, it was copied illegally and republished in violation of United States & international copyright and trademark law. The original version of this report can be viewed at https://www.dailypolitical.com/2017/09/16/cytomx-therapeutics-inc-ctmx-downgraded-by-valuengine-to-sell.html.
In other CytomX Therapeutics news, CFO Debanjan Ray sold 2,500 shares of the company’s stock in a transaction dated Monday, July 3rd. The shares were sold at an average price of $15.47, for a total transaction of $38,675.00. Following the sale, the chief financial officer now directly owns 22,126 shares of the company’s stock, valued at $342,289.22. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, Director Frederick W. Gluck sold 5,000 shares of the company’s stock in a transaction dated Monday, June 26th. The stock was sold at an average price of $14.61, for a total transaction of $73,050.00. The disclosure for this sale can be found here. Insiders have sold 70,229 shares of company stock worth $1,145,499 over the last ninety days. Insiders own 4.70% of the company’s stock.
A number of institutional investors have recently modified their holdings of CTMX. Legal & General Group Plc grew its stake in CytomX Therapeutics by 28.6% during the second quarter. Legal & General Group Plc now owns 6,448 shares of the biotechnology company’s stock worth $101,000 after buying an additional 1,434 shares during the last quarter. Hillsdale Investment Management Inc. bought a new stake in CytomX Therapeutics during the first quarter worth about $159,000. First Quadrant L P CA bought a new stake in CytomX Therapeutics during the second quarter worth about $160,000. Cubist Systematic Strategies LLC bought a new stake in CytomX Therapeutics during the second quarter worth about $174,000. Finally, Goldman Sachs Group Inc. bought a new stake in CytomX Therapeutics during the first quarter worth about $190,000. 59.97% of the stock is currently owned by hedge funds and other institutional investors.
About CytomX Therapeutics
CytomX Therapeutics, Inc is a clinical-stage, oncology-focused biopharmaceutical company. The Company uses its Probody technology platform to create cancer immunotherapies against clinically validated targets, as well as to develop cancer therapeutics against difficult-to-drug targets. Its pipeline is focused on the development of therapies in a set of modalities: Probody cancer immunotherapies, Probody drug conjugates, T-cell engaging Probody bispecifics and ProCAR-NK cell therapies.
Receive News & Ratings for CytomX Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytomX Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.